Literature DB >> 7334360

Local production of mumps IgG and IgM antibodies in the cerebrospinal fluid of meningitis patients.

P Ukkonen, M L Granström, J Räsänen, E M Salonen, K Penttinen.   

Abstract

Immunoglobulin G (IgG) and M (IgM) antibodies against mumps virus were measured by an enzyme-linked immunosorbent assay (ELISA) in the serum and cerebrospinal fluid (CSF) specimens of patients with mumps meningitis. The CSF IgG antibodies correlated well with the respective antibody titers in serum. On the contrary, in only about half of the patients a moderate correlation was found between the CSF and serum IgM antibody titers, while the other patients did not have detectable mumps IgM antibodies in CSF irrespective of intermediate to high titers in serum. Two different immunologic mechanisms may be involved in these two groups which, however, did not show any clinical differences. The lack of IgM antibodies in the CSF of many patients diminished the value of CSF in the laboratory diagnosis of mumps meningitis compared to use of serum specimens. Intrathecal synthesis of mumps IgG antibodies was demonstrated in 83% of the patients, and of IgM antibodies in at least 67% of those patients with detectable IgM antibodies in CSF. The ratio between mumps IgG and IgM antibodies was higher in CSF than in serum, suggesting that the synthesis of IgG antibodies in central nervous system was more efficient than that of IgM antibodies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334360     DOI: 10.1002/jmv.1890080406

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  15 in total

1.  Immunological differentiation between neuroborreliosis and multiple sclerosis.

Authors:  J Heller; G Holzer; K Schimrigk
Journal:  J Neurol       Date:  1990-12       Impact factor: 4.849

2.  Guillain-Barré syndrome following streptokinase therapy.

Authors:  R Kaiser; R Kaufmann; M Czygan; H Lang; C H Lücking
Journal:  Clin Investig       Date:  1993-10

3.  Spinal fluid lymphocytes responsive to autologous and allogeneic cells in multiple sclerosis and control individuals.

Authors:  G Birnbaum; L Kotilinek; M Schwartz; M Sternad
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

4.  Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis.

Authors:  J Alvarez-Cermeño; J M Echevarría; L M Villar; I Lázaro; A Bootello; P González-Porque
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-10       Impact factor: 10.154

5.  Intrathecal synthesis of virus-specific oligoclonal antibodies in patients with enterovirus infection of the central nervous system.

Authors:  R Kaiser; R Dörries; R Martin; U Fuhrmeister; K F Leonhardt; V ter Meulen
Journal:  J Neurol       Date:  1989-10       Impact factor: 4.849

6.  Proportions of immunoglobulin isotypes in paralytic poliomyelitis and after vaccination.

Authors:  I Julkunen; P Ukkonen; M Stenvik; T Hovi; L Renkonen; O Mäkelä
Journal:  J Clin Immunol       Date:  1987-07       Impact factor: 8.317

7.  Intrathecal immune response and virus-specific immunoglobulin M antibodies in laboratory diagnosis of acute poliomyelitis.

Authors:  M Roivainen; M Agboatwalla; M Stenvik; T Rysä; D S Akram; T Hovi
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

8.  Rapid diagnosis of LaCrosse encephalitis: detection of specific immunoglobulin M in cerebrospinal fluid.

Authors:  T I Dykers; K L Brown; C B Gundersen; B J Beaty
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

9.  Immunoglobulin G subclass preference of intrathecally produced HIV-specific oligoclonal antibodies.

Authors:  R Kaiser; R Dörries; B Ruf; H D Pohle; R Martin; V ter Meulen
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

10.  Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques.

Authors:  S Sopper; U Sauer; S Hemm; M Demuth; J Müller; C Stahl-Hennig; G Hunsmann; V ter Meulen; R Dörries
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.